Actively Recruiting
Mechanisms And Prognosis of Stroke-Heart Syndrome
Led by Chensheng Pan · Updated on 2025-05-01
658
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
Sponsors
C
Chensheng Pan
Lead Sponsor
N
National Natural Science Foundation of China
Collaborating Sponsor
AI-Summary
What this Trial Is About
The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.
CONDITIONS
Official Title
Mechanisms And Prognosis of Stroke-Heart Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted within 48 hours of stroke onset confirmed by CT or MRI, including acute ischemic and hemorrhagic stroke.
- Moderate-to-severe stroke with a National Institutes of Health Stroke Scale (NIHSS) score of 5 or greater.
You will not qualify if you...
- Previous focal brain injury such as stroke, brain surgery, or traumatic brain injury.
- Brain dysfunction caused by neurological disorders other than stroke, including brain tumors, epilepsy, or Parkinson's disease.
- Transient ischemic attack (TIA) or subarachnoid hemorrhage (SAH).
- History of cardiac diseases including coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms.
- Presence of systemic diseases such as renal failure with eGFR less than 30, autoimmune disorders, or severe infections.
- History of dementia, depression, or other psychiatric disorders.
- Poor compliance or inability to cooperate with follow-up requirements.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Neurology, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
C
Chensheng Pan, M.D.
CONTACT
Z
Zhou Zhu, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here